Business context and reporting period
The supplied filing is Virios Therapeutics, Inc.’s unaudited Form 10-Q for the quarter and six months ended June 30, 2021—not a filing under the requested name Dogwood Therapeutics, Inc. Verify the issuer and filing identity. Virios is a pre-revenue, clinical-stage biotechnology company developing IMC-1, a fixed-dose combination of famciclovir and celecoxib for fibromyalgia.
Financial results and liquidity
| Metric | Three months ended June 30, 2021 | Six months ended June 30, 2021 | Comparable 2020 period |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Research and development expense | $3.21 million | $4.92 million | $0.02 million and $0.05 million, respectively |
| General and administrative expense | $1.08 million | $2.43 million | $0.52 million and $0.87 million, respectively |
| Net loss | $4.28 million | $7.34 million | $0.65 million and $1.12 million, respectively |
| Operating cash used | Not separately provided | $7.86 million | $1.05 million for six months |
At June 30, 2021, cash was $21.84 million, total current assets were $23.76 million, current liabilities were $0.91 million, and stockholders’ equity was $22.86 million. The company reported no debt outstanding. No gross or operating margin is meaningful given zero revenue.
Material changes versus the prior comparable period
Six-month operating expenses rose to $7.34 million from $0.92 million, primarily as clinical-trial, toxicology, salary, drug-development and public-company costs increased. Six-month net loss grew to $7.34 million from $1.12 million; operating cash use increased to $7.86 million from $1.05 million. Cash declined by $7.96 million during the first half of 2021, from $29.80 million at year-end 2020. The 2020 comparison periods predate the December 2020 corporate conversion and IPO.
Outlook, risks and notable items
- The company reported that the first patient was dosed in its Phase 2b FORTRESS fibromyalgia study in June 2021. It is enrolling 460 female patients and projected top-line results in mid-2022.
- Management estimated June 30 cash would fund operations through the end of 2022 and support completion of Phase 2b and planning for a Phase 3 study. The notes separately state cash and IPO proceeds are expected to fund operations for at least the next 12 months. The company expects ongoing losses and will need additional capital for later development and commercialization; no external financing is committed.
- COVID-19 had not materially affected operations to date, but management cautioned that future disruptions could delay enrollment or trial completion. Clinical development, third-party execution, regulatory approval and financing remain key uncertainties.
- Disclosure controls were judged ineffective because of a continuing material weakness involving segregation of duties, financial-statement reporting and general technology controls. The company described remediation steps, but did not assure they would be sufficient.
- No pending legal actions were reported as of June 30, 2021. The filing disclosed a related-party consulting relationship with the Chief Medical Officer’s firm, which received $77,816 in the quarter and $142,282 in the six-month period.
Important facts for investors to verify
- Confirm whether this Virios Therapeutics filing is the intended filing for Dogwood Therapeutics.
- Check subsequent updates to FORTRESS enrollment, completion timing and the projected mid-2022 results.
- Reconcile management’s differing runway statements and assess cash needs against clinical-trial spending and financing availability.
- Review progress in remediating the material weakness in internal controls.
- Confirm the status of future clinical-development funding and any changes to the company’s financing plans.